Merck KGaA Profit Beats Estimates on Cost-Cutting

May 14 (Bloomberg) -- Merck KGaA, the German maker of cancer drug Erbitux, said first-quarter profit rose on higher-than-expected savings from a reorganization program, and forecast it will achieve 2014 targets a year ahead of schedule. Mark Barton reports on Bloomberg Television's "Countdown." (Source: Bloomberg)

China's Challenges: PMI Weakens to Lowest in Three Years
04:58 - China’s manufacturing conditions slipped to the weakest level in more than three years as sluggishness in the nation’s old growth drivers add to risks facing the government’s growth target. Bloomberg's Stephen Engle takes a look at the numbers on "Trending Business." (Source: Bloomberg)
  • What China’s PMI Report Tells Us About the Economy
  • China's 'Old Manufacturing' Suffering: IHS's Jackson
  • China Outlook: Long-Term Plays for Investors